Experimental combo targets tough blood cancers
NCT ID NCT05636514
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This early-phase trial is testing whether combining two drugs—decitabine/cedazuridine (already approved for MDS) and the experimental drug defactinib—is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukemia. Twelve participants will receive the combination for up to six cycles. The main goal is to find the highest safe dose and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Concord Repatriation and General Hospital
RECRUITINGSydney, New South Wales, 2139, Australia
Contact
-
Nepean Hospital
RECRUITINGSydney, New South Wales, 2747, Australia
Contact
-
Prince of Wales Hospital
RECRUITINGSydney, New South Wales, 2031, Australia
Contact
-
Royal Prince Alfred Hospital
RECRUITINGSydney, New South Wales, 2050, Australia
Contact
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
decitabine/cedazuridine (ASTX727) and defactinib (VS-6063)
What this could lead to
If this combination is safe and effective, it could offer a new treatment option for people with high-risk MDS, AML, or CMML.
What could go wrong
This is a very early phase 1 trial with only 12 participants, so it is mainly testing safety and dosing. The combination may not work better than existing treatments, and side effects could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.